Immunotherapy of colorectal cancer: challenges for therapeutic efficacy
Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the second type in terms of mortality. Over 1.8 millions of CRC cases and 881.000 CRC-related deaths were estimated to occur in 2018 in the World [1]. Despite significant improvements in CRC treatment, the prognosis of patients with metastatic CRC (mCRC) remains poor, with a median overall survival (OS) of approximately 30 months [2]. For this reason, novel and more effective therapeutic strategies are necessary for metastatic disease.
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Davide Ciardiello, Pietro Paolo Vitiello, Claudia Cardone, Giulia Martini, Teresa Troiani, Erika Martinelli, Fortunato Ciardiello Tags: Anti-Tumour Treatment Source Type: research